FDA’s Hamburg Says EMA Could Be Model For Global Regulatory Coalition
This article was originally published in The Pink Sheet Daily
Executive Summary
Outgoing commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.
You may also be interested in...
The Atypical Commissioner Turns Out Well: Hamburg Receives Mostly Fond Farewell
Margaret Hamburg’s public health, as opposed to academic medicine, background was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and significant praise for new initiatives such as the breakthrough therapy program.
FDA/EMA Bioequivalence Collaboration Is Narrow In Scope, Wide In Reach
In contrast to the existing inspection program for clinical trials, sites around the globe will be targeted.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.